• Jon I Einarsson, Bjarki O Audbergsson, and Adalbjorn Thorsteinsson.
• Department of Obstetrics and Gynecology, Landspitali-University Hospital, Reykjavik, Iceland. jeinarsson@partners.org
• J Minim Invasive Gynecol. 2008 Jan 1;15(1):26-31.

Study ObjectiveWe sought to estimate effectiveness of transdermal scopolamine to prevent postoperative nausea and vomiting after gynecologic laparoscopy.DesignPatients were randomized to receive preoperative transdermal scopolamine or placebo. Main outcome measure was incidence of nausea during the first 24 hours postoperatively. Wilcoxon rank sum, Student t, chi2, and Fischer exact tests were used for data analysis (Canadian Task Force classification IA).SettingAcademic teaching hospital.PatientsA total of 48 patients undergoing gynecologic laparoscopy were studied.InterventionsRandomized administration of transdermal Scopolamine or placebo in patients having gynecologic laparoscopic surgery.Measurements And Main ResultsPatients in the scopolamine group had significantly less incidence of nausea (20.8% vs 62.5%, p = .003) and vomiting (8.3% vs 37.5%, p = .016) during the first 24 hours after surgery. Number needed to treat was 3 (95% CI 1.5, 6.1) for nausea and 4 (95% CI 1.9, 14.6) for vomiting. Symptoms of visual disturbance and dry mouth were more common in the scopolamine group.ConclusionScopolamine patch significantly reduces incidence and severity of nausea and vomiting in the first 24 hours after gynecologic laparoscopic surgery.

19 keywords...

hide…